These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 14871994)
21. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Yokota T; Matsuzaki Y; Miyazawa K; Zindy F; Roussel MF; Sakai T Oncogene; 2004 Jul; 23(31):5340-9. PubMed ID: 15107822 [TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors repress chondrosarcoma cell proliferation. Zhu J; Gu J; Ma J; Xu Z; Tao H J BUON; 2015; 20(1):269-74. PubMed ID: 25778327 [TBL] [Abstract][Full Text] [Related]
23. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Ryu JK; Lee WJ; Lee KH; Hwang JH; Kim YT; Yoon YB; Kim CY Cancer Lett; 2006 Jun; 237(1):143-54. PubMed ID: 16009488 [TBL] [Abstract][Full Text] [Related]
24. Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells. Takai N; Ueda T; Nishida M; Nasu K; Narahara H Anticancer Res; 2006; 26(2A):939-45. PubMed ID: 16619490 [TBL] [Abstract][Full Text] [Related]
25. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197 [TBL] [Abstract][Full Text] [Related]
26. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest. Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863 [TBL] [Abstract][Full Text] [Related]
27. Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia. Shao N; Zou J; Li J; Chen F; Dai J; Qu X; Sun X; Ma D; Ji C Leuk Lymphoma; 2012 Sep; 53(9):1769-78. PubMed ID: 22303878 [TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo. Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034 [TBL] [Abstract][Full Text] [Related]
29. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
30. CBHA is a family of hybrid polar compounds that inhibit histone deacetylase, and induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Takai N; Ueda T; Nishida M; Nasu K; Matsuda K; Kusumoto M; Narahara H Oncology; 2006; 70(2):97-105. PubMed ID: 16601366 [TBL] [Abstract][Full Text] [Related]
31. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915 [TBL] [Abstract][Full Text] [Related]
32. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. Albino AP; Juan G; Traganos F; Reinhart L; Connolly J; Rose DP; Darzynkiewicz Z Cancer Res; 2000 Aug; 60(15):4139-45. PubMed ID: 10945621 [TBL] [Abstract][Full Text] [Related]
33. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. Takai N; Ueda T; Nishida M; Nasu K; Narahara H Int J Mol Med; 2006 Feb; 17(2):323-9. PubMed ID: 16391833 [TBL] [Abstract][Full Text] [Related]
34. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052 [TBL] [Abstract][Full Text] [Related]
35. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934 [TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Suenaga M; Soda H; Oka M; Yamaguchi A; Nakatomi K; Shiozawa K; Kawabata S; Kasai T; Yamada Y; Kamihira S; Tei C; Kohno S Int J Cancer; 2002 Feb; 97(5):621-5. PubMed ID: 11807787 [TBL] [Abstract][Full Text] [Related]
37. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Siavoshian S; Segain JP; Kornprobst M; Bonnet C; Cherbut C; Galmiche JP; Blottière HM Gut; 2000 Apr; 46(4):507-14. PubMed ID: 10716680 [TBL] [Abstract][Full Text] [Related]
38. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943 [TBL] [Abstract][Full Text] [Related]
39. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Shen JC; Klein RD; Wei Q; Guan Y; Contois JH; Wang TT; Chang S; Hursting SD Mol Carcinog; 2000 Oct; 29(2):92-102. PubMed ID: 11074606 [TBL] [Abstract][Full Text] [Related]
40. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications. Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]